Knee osteoarthritis (KOA) is a prevalent musculoskeletal condition characterized by a significant therapeutic gap between the failure of conservative medical therapies and surgical arthroplasty. Contemporary evidence supports a model in which chronic synovitis and pathologic neoangiogenesis, closely coupled to perivascular nociceptive nerve growth, serve as significant contributors of pain and peripheral sensitization in KOA. Genicular artery embolization has emerged as a targeted, joint-preserving vascular intervention performed by interventional radiologists that directly addresses the inflammatory and neurovascular components of KOA. The purpose of this societal-endorsed position statement is to synthesize the current knowledge base for genicular artery embolization and review its biologic rationale, clinical evidence, technical considerations, safety profile, and evolving regulatory landscape.
(1) Background: Sympathetic overactivity is a major contributor to resistant hypertension (RH). According to animal studies, sympathetic overactivity increases immune responses, thereby aggravating hypertension and cardiovascular outcomes. Renal denervation (RDN) reduces sympathetic nerve activity in RH. Here, we investigate the effect of RDN on T-cell signatures in RH. (2) Methods: Systemic inflammation and T-cell subsets were analyzed in 17 healthy individuals and 30 patients with RH at baseline and 6 months after RDN. (3) Results: The patients with RH demonstrated higher levels of pro-inflammatory cytokines and higher frequencies of CD4+ effector memory (TEM), CD4+ effector memory residential (TEMRA) and CD8+ central memory (TCM) cells than the controls. After RDN, systolic automated office blood pressure (BP) decreased by −17.6 ± 18.9 mmHg. Greater BP reductions were associated with higher CD4+ TEM (r −0.421, p = 0.02) and CD8+ TCM (r −0.424, p = 0.02) frequencies at baseline. The RDN responders, that is, the patients with ≥10mmHg systolic BP reduction, showed reduced pro-inflammatory cytokine levels, whereas the non-responders had unchanged inflammatory activity and higher CD8+ TEMRA frequencies with increased cellular cytokine production. (4) Conclusions: The pro-inflammatory state of patients with RH is characterized by altered T-cell signatures, especially in non-responders. A detailed analysis of T cells might be useful in selecting patients for RDN.
13 May 2024 in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
Osteoarthritis (OA) is a chronic degenerative disease significantly impacting both patient quality of life and socioeconomics. Traditional treatment options, including pharmacological and surgical interventions, are often limited. Advancements in our understanding of the pathological mechanisms behind OA indicate the involvement of pathological angiogenesis. Transarterial microembolization (TAME), a minimally invasive radiological procedure, may present an innovative therapeutic approach. This review aims to consolidate current knowledge and experiences regarding TAME as a therapeutic modality for alleviating chronic joint pain associated with OA. It explores the role of TAME, focusing on its indications, patient selection, clinical outcomes, and future perspectives. Potential complications and associated risks are systematically addressed, alongside proposed strategies for risk mitigation and effective management.The presented patient cases originate from our institution, supplemented by a thorough review of relevant literature retrieved from PubMed.TAME represents a promising therapeutic approach, providing relief from the burden of joint diseases and substantially enhancing patient quality of life. Clinical outcomes emphasize the efficacy and safety of TAME in mitigating pain and improving functional capabilities in patients with chronic joint pain associated with OA. With mounting evidence of its therapeutic benefits and applicability to numerous joint-related pathologies, TAME offers a valuable addition to the arsenal of treatments for these conditions.
Locoregional therapy options for CCA are used, in particular, for non-resectable tumors and aim to reduce tumor viability or delay tumor growth and ultimately prolong overall survival. In addition to local ablative procedures such as radiofrequency- or microwave-ablation, transarterial procedures such as transarterial embolization (TAE), transarterial chemoembolization (TACE), or selective internal radiotherapy (SIRT) play a major role. In particular, in combination with advances in molecular medicine and immunotherapy, there has been a further development in the therapy of primary malignant liver tumors in recent years. In this review, we analyze data from recent studies and examine the implications for therapy of CCA, particularly with regard to the combination of locoregional therapies with modern systemic therapies.
9 September 2025 in CardioVascular and Interventional Radiology
Chronic tendinopathies remain challenging to treat, especially when conservative measures fail. Transcatheter arterial microembolization (TAME) has emerged as a treatment alternative for tendinopathies, with its efficacy demonstrated in a meta-analysis across various indications [1]. Sugihara et al. presented the first multicenter retrospective analysis evaluating TAME for patients with chronic achilles tendinopathy (AT) refractory to conservative management [2]. Eighty-two patients from four institutions underwent TAME with imipenem/cilastatin. Hypervascularity was assessed using Doppler ultrasound and digital subtraction angiography (DSA), with the introduction of a novel angiographic grading system ranging from Grade 0 (no blush) to Grade 3 (massive blush with early venous return). Over 24 months, pain scores (Numeric rating scale; NRS) improved from 6.7 to 1.5, Victorian Institute of Sports Assessment (VISA-A) scores from 48.4 to 82.2, and clinical success-C 50% NRS reduction at 12 months-was achieved in 81.7% of patients. Until now, evidence of TAME for AT has been confined to cohorts with short-term follow-up [1]. This work provides the first long-term data in a large cohort of patients with AT, demonstrating not only durable clinical benefit &
21 May 2025 in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
Therapeutic options for the treatment of visceral artery aneurysms (VAA) and pseudoaneurysms (VAPA) include either a surgical or endovascular approach, depending on specific characteristics of both the aneurysm and the individual patient. The therapeutic use of flow diverters (FD) has already yielded excellent results. The purpose of this study is to evaluate initial experiences regarding the use of a novel abdominal FD. In this observational multicenter study, the data of nine consecutive patients with visceral or abdominal aneurysms from four interventional centers, treated with the Derivo peripher FD, between 2022 and 2024 were evaluated regarding the technical feasibility and procedural performance of the device, safety, and treatment outcome. The average size of the treated aneurysms was 18±11 mm, and the affected vessels were the splenic (55.6%), the hepatic (22.2%), the gastroduodenal (11.1%), and the renal artery (11.1%). Complete aneurysm occlusion was observed in every patient after three months, and mid-term follow-up after 12 months was available for eight patients. All FDs remained patent during the follow-up period. No major complications or adverse events arose. The overall mortality rate was 0%. Based on our initial multicenter experience, endovascular treatment of abdominal and visceral aneurysms with an FD was found to be effective and safe. The remarkable results in terms of aneurysm occlusion and low complication rates are promising.